bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 6 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 6. Recovery of MET protein levels by inhibition of MET/HGF signaling in HCC2108, a lung adenocarcinoma cell line.
Supplementary Figure 5 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 5. Recovery of MET protein levels by inhibition of MET/HGF signaling.
Supplementary Tables S1-S5 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Table S1 provides data on biochemical properties of the scTRAIL molecules, Table S2 provides data on binding properties of the scTRAIL molecules, Table 3 provides data on the EC50 values of cell death induction of the scTRAIL molecules in the presence of blocking antibodies, Table S4 provides data on the pharmacokinetic properties, and Table S5 provides data on drug exposure of the scTRAIL molecules in tumor-bearing mice.
Supplementary Figure S7 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S7 provides data on safety of the treatments with EGFR-targeted scTRAIL fusion proteins and Fc-scTRAIL in combination with bortezomib.
Supplementary Figure 1 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 1. HGF attenuates sensitivity to erlotinib in HCC827 cells.
Supplementary Figure S4 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S4 provides data on a comparison of bioactivity of dimeric EHD2-scTRAIL and the high molecular weight fraction.
Supplementary Table S1 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Source and working dilutions of the primary antibodies used for Western blotting, immunofluorescence and immunohistochemical staining and pull-down assay.
Supplementary Figure S2 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S2 provides data on target binding of scTRAIL molecules in ELISA
Supplementary Figure 6 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S6 provides data on biochemical and functional characterization of Fc-scTRAIL8M.
Supplementary Figure S4 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Putative molecular pathway through which GSK3beta promotes glioblastoma cell migration and invasion.
Supplementary Figure S2 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

ffect of GSK3beta inhibition on morphology, subcellular localization of F-actin and Rac1 and lamellipodia formation in glioblastoma cells.
Supplementary Figure legends from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Supplementary Figure legends
Supplementary Figure 5 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S5. (A) PM030779 did not induce RNA Pol II degradation and DNA breaks. For the kinetics of RNA synthesis A549 cells were treated with the compound or DMSO in normal growth medium for 0, 30, 45, 60, 90 and 120 minutes and pulsed with 5ÂµCi/ml [3H] uridine for 30min. Data are mean{plus minus}SEM values (triplicates, n=1). We have also evaluated Pol IIo and Pol IIa by western blot after treatment of A549 cells with PM030779 (30nM) for different time intervals. Finally, we performed Tail Moment quantification of A549 cells treated with PM030779 at 4h using the TriTek CometScore Freeware software. The Comet assay was performed in neutral conditions to detect double strand breaks (DSBs). For each condition a minimum of 100 cells were analysed, and the experiment was repeated in duplicate. (B) RNA synthesis inhibition, Pol II degradation and DNA breaks formation after treatment of OGROV-1 and IGROV-ET cancer cells with lurbinectedin For the kinetics of RNA synthesis both cell lines were treated with lurbinectedin (30nM) or DMSO in normal growth medium for 0, 30, 45, 60, 90 and 120 minutes and pulsed with 5ÂµCi/ml [3H] uridine for 30min. Data are mean{plus minus}SEM values (triplicates, n=1). We have also evaluated Pol IIo and Pol IIa by western blot in both cell lines after treatment with lurbinectedin (Lur) (30nM) for different time intervals. Finally, we performed Tail Moment quantification of cells treated with Lur (30nM) at 4h using the TriTek CometScore Freeware software. For each condition a minimum of 100 cells were analysed, and the experiment was repeated in duplicate.
Figure S6 from Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Authors: Le Clorennec Christophe , Bazin Hervé , Dubreuil Olivier , Larbouret Christel , Ogier Charline , Lazrek Yassamine , Garambois Véronique , Poul Marie-Alix , Mondon Philippe , Barret Jean-Marc , Mathis Gérard , Prost Jean-François , Pèlegrin André , Chardès Thierry
Published: April 2023

Supplemental Fig.S6. Effect of NRG1 on cell viability of the cancer cell lines BxPC3, HCC-1806, A549 and HPAC. Cells were plated in medium with 1% fetal calf serum and then cultured with increasing concentrations of NRG1 for 5 days. Cell proliferation was measured using the MTS assay.
Supplementary Figure 3 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S3. NER machinery remains active in the presence of DRB. A dual incision assay (48) was performed by the co-incubation of NER (XPC, TFIIH, XPA, RPA, XPG and XPF) components with increasing amount of DRB (10, 20, 50 and 100ÂµM).
Supplementary Figure 2 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S2. Lurbinectedin inhibits RNA synthesis and promotes Pol II degradation in different cancer cell lines. (A) Kinetics of RNA synthesis. Ewing sarcoma (A673), colon (HCT-116), cervix (HeLa) and breast (MDA-MB-231) cancer cells were treated with lurbinectedin or vehicle (DMSO) in normal growth medium for 0, 30, 45, 60, 90 and 120 minutes and pulsed with 5ÂµCi/ml [3H] uridine for 30min. Data are mean {plus minus} SEM values (triplicates, n=1). (B) Western blot analyses of Pol II in the same panel of cancer cell lines after 1, 2, 3 or 4 hours of lurbinectedin (30nM) treatment.
Supplementary Figure 1 from Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells
Authors: Santamaría Nuñez Gema , Robles Carlos Mario Genes , Giraudon Christophe , Martínez-Leal Juan Fernando , Compe Emmanuel , Coin Frédéric , Aviles Pablo , Galmarini Carlos María , Egly Jean-Marc
Published: April 2023

Figure S1. Structures of (A) PM030779 and (B) PM120306; both compounds are analogues of lurbinectedin. (C) Antiproliferative activity of PM120306 in A549 lung cancer cell line. Cell viability was analysed 72 h post lurbinectedin treatment by MTT assay. IC50 value was determined as being 49.9 nM (D) Western blot analyses of A549 cell extracts after (1h and 4h) treatment with either lurbinectedin (Lur, 30nM) or the biotinylated analog (PM120306, 30nM); NT: non-treated cells. The same antibody has been used to detect the hyper-phosphorylated (IIo) and hypo-phosphorylated (IIa) forms of the Rpb1 subunit of Pol II; Î²-Tubulin: Tub.
Supplementary Figure 3 from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

TRX-E-002-1 given daily at 150 mg/kg is toxic. Once tumors were established and detected by live imaging, mice were treated i.p. with 150 mg/kg TRX-E-002-1 three times weekly. (A) tumor growth curves as measured using mCherry fluorescence area. * p < 0.0001 ; (B) quantification of total i.p. tumor burden at end of study, * p = 0.1245; (C) change in animal weight by the end of study, * p = 0.0013; (D) WBC count, * p < 0.001; (E) Neutrophil count; (F) Lymphocyte count.
Supplemental Tables S1-S9 from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Authors: Chen Ping , Lee Nathan V. , Hu Wenyue , Xu Meirong , Ferre Rose Ann , Lam Hieu , Bergqvist Simon , Solowiej James , Diehl Wade , He You-Ai , Yu Xiu , Nagata Asako , VanArsdale Todd , Murray Brion W.
Published: April 2023

Table S1. Statistics for the crystallographic analysis; Table S2. Biochemical and cellular potencies of the second generation CDK-directed drug AG-024322; Table S3. In vitro analysis of binding potency of abemaciclib, dinaciclib, and palbociclib to non-kinase proteins; Table S4. Broad kinase selectivity of selective CDK4/6 drugs; Table S5. Biochemical dose-response follow-up was conducted for a subset of kinases inhibited by the three CDK4/6 drugs using a Km concentration of ATP (Carna Biosciences) (CDK proteins excluded); Table S6. Kinase selectivity toward endogenous human kinases using irreversible ATP analog target engagement assay; Table S7. Biochemical potencies of selective CDK4/6 drugs palbociclib (PD-0332991); Table S8. Human pharmacokinetic properties of CDK-targeted drugs; Table S9. Isothermal titration calorimetry results for CDK-directed drugs binding to CDK6 in the absence of cyclin D.
Supplemental Methods from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Authors: Chen Ping , Lee Nathan V. , Hu Wenyue , Xu Meirong , Ferre Rose Ann , Lam Hieu , Bergqvist Simon , Solowiej James , Diehl Wade , He You-Ai , Yu Xiu , Nagata Asako , VanArsdale Todd , Murray Brion W.
Published: April 2023

Detailed description of the methods used in the manuscript
SupMovie2b from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

3-D spheroids treated with TRX-E-002-1
Supplementary Materials and Methods, Supplementary Tables 1 and 2, and Supplementary Figures 1 through 8 from Differential Therapeutic Effects of Anti–VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing
Authors: Alishekevitz Dror , Bril Rotem , Loven David , Miller Valeria , Voloshin Tali , Gingis-Velistki Svetlana , Fremder Ella , Scherer Stefan J. , Shaked Yuval
Published: April 2023

PDF - 5513KB, Supplemental Materials & Methods; Supplemental Table 1: Evaluation of MTD chemotherapy in BALB/c mice; Supplemental Table 2: Analysis of changes in the levels of pro-angiogenic cytokines in plasma of mice treated with FOLFOX chemotherapy; Supplemental Figure 1: Growth kinetics of micrometastatic lesions in the lungs of mice implanted with 4T1 or CT26 primary tumors; Supplemental Figure 2: Growth kinetics of advanced macrometastatic lesions in the lungs of mice intravenously injected with 4T1 or CT26 tumor cells; Supplemental Figure 3: The kinetics of CEP levels in the blood of mice treated with FOLFOX or GEM/CDDP; Supplemental Figure 4: Body weight in mice bearing 4T1 or CT-26 tumors following treatment with FOLFOX or GEM/CDDP with or without anti-VEGF-A antibodies; Supplemental Figure 5: The number of MDSCs colonizing 4T1 and CT26 tumors following treatment with FOLFOX or GEM/CDDP with or without anti-VEGF-A antibody; Supplemental Figure 6: Metastasis count in the lungs of mice bearing 4T1 and CT26 experimental or spontaneous metastatic models; Supplemental Figure 7: VEGF-A does not induce invasion of 4T1 and CT26 cells; Supplemental Figure 8: Anti- VEGF blocked FOLFOX-induced liver metastases in LM2-4 tumors.
SupMovie2a from TRX-E-002-1 Induces c-Jun–Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo
Authors: Alvero Ayesha B. , Heaton Andrew , Lima Eydis , Pitruzzello Mary , Sumi Natalia , Yang-Hartwich Yang , Cardenas Carlos , Steinmacher Sahra , Silasi Dan-Arin , Brown David , Mor Gil
Published: April 2023

3-D spheroids treated with vehicle control
Supplementary File 2_Gene Sets from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Literature derived gene sets from which curated gene set list created.
Supplementary Figure S4 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S4. BRG1-BRD inhibits ÃŽÂ³-H2AX formation and DSB repair in irradiated A549 cells and this activity is enhanced by dimerization.
Supplementary Figures S4-S12 from Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
Authors: Hassan Saima , Esch Amanda , Liby Tiera , Gray Joe W. , Heiser Laura M.
Published: April 2023

Supplementary Figure S4. Cell cycle distributions for veliparib, olaparib, and talazoparib, in A) HCC1143, B) MDAMB231, and C) HCC1806; Supplementary Figure S5. Cell cycle histograms for veliparib, olaparib, and talazoparib, in A) HCC1143, B) MDAMB231, and C) HCC1806 at selected concentrations; Supplementary Figure S6. Cleaved-PARP expression; Supplementary Figure S7. Representative EC50 dose-response curves of normalized percentage of cells positive for 53BP1 for veliparib, olaparib, and talazoparib in A) HCC1143, B) MDAMB231, C) HCC1806, D) HCC1395, and E) MDAMB436; Supplementary Figure S8. IC50 and EC50 values compiled for 8 breast cancer cell lines, for veliparib, olaparib, and talazoparib; Supplementary Figure S9. For each PARP inhibitor, correlations between IC50 values and A) EC50 values for % positive 53BP1, B) EC50 values for 53BP1 foci, C) EC50 values for % positive for cleaved-PARP; Supplementary Figure S10. Summary of Gene Set Enrichment Analysis (GSEA); Supplementary Figure S11. Enrichment plots after gene set enrichment analysis; Supplementary Figure S12. A) Presence of mutations in 63 gene-set in triple-negative breast cancer patients; B) Mutational frequency of 63 pathway enriched genes in triple-negative breast cancer (TNBC), ER-negative, ER-positive, basal, luminal B, and luminal A breast cancer subtypes.
Supplementary Figure S2 from Targeting BRG1 Chromatin Remodeler via Its Bromodomain for Enhanced Tumor Cell Radiosensitivity In Vitro and In Vivo
Authors: Kwon Su-Jung , Lee Seul-Ki , Na Juri , Lee Shin-Ai , Lee Han-Sae , Park Ji-Hye , Chung June-Key , Youn Hyewon , Kwon Jongbum
Published: April 2023

Supplementary Figure S2. BRG1-BRD radiosensitizes MDA-MB-231 and A549 cells and this activity is enhanced by dimerization.
Supplementary Information from Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
Authors: Pillow Thomas H. , Schutten Melissa , Yu Shang-Fan , Ohri Rachana , Sadowsky Jack , Poon Kirsten Achilles , Solis Willy , Zhong Fiona , Del Rosario Geoffrey , Go Mary Ann T. , Lau Jeffrey , Yee Sharon , He Jintang , Liu Luna , Ng Carl , Xu Keyang , Leipold Douglas D. , Kamath Amrita V. , Zhang Donglu , Masterson Luke , Gregson Stephen J. , Howard Philip W. , Fang Fan , Chen Jinhua , Gunzner-Toste Janet , Kozak Katherine K. , Spencer Susan , Polakis Paul , Polson Andrew G. , Flygare John A. , Junutula Jagath R.
Published: April 2023

Supplementary Figures S1-S5, Supplementary Materials and Methods
Supplemental Figure Legends from Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
Authors: Abu Aboud Omran , Chen Ching-Hsien , Senapedis William , Baloglu Erkan , Argueta Christian , Weiss Robert H.
Published: April 2023

Supplemental Figure Legends
Supplemental Tables S1-S3 from The Selective Intravenous Inhibitor of the MET Tyrosine Kinase SAR125844 Inhibits Tumor Growth in MET-Amplified Cancer
Authors: Egile Coumaran , Kenigsberg Mireille , Delaisi Christine , Bégassat Françoise , Do-Vale Véronique , Mestadier Jessica , Bonche Fabrice , Bénard Tsiala , Nicolas Jean-Paul , Valence Sandrine , Lefranc Céline , Francesconi Elisa , Castell Christelle , Lefebvre Anne-Marie , Nemecek Conception , Calvet Loreley , Goulaouic Hélène
Published: April 2023

Supplemental Tables S1-S3. Table S1 describes the antiproliferative activity of SAR125844 on a panel of cell lines and the known genetic alterations of MET and other oncogenes or tumor suppressor genes for these cell lines. Table S2 describes the antiproliferative activity of SAR125844 upon various times of exposure in Hs 746T MET-amplified tumor cell line. Table S3 describes tumor exposure over plasma exposure ratios for SAR125844, JNJ-38877605 and PF-04217903 MET inhibitors.
Supplementary Figure 1 from Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
Authors: Neel Nicole F. , Stratford Jeran K. , Shinde Vaishali , Ecsedy Jeffrey A. , Martin Timothy D. , Der Channing J. , Yeh Jen Jen
Published: April 2023

PDF - 112K, MLN8237 structure and additional response data.
Supplementary Table 3 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Table 3. Analysis of gene expression with microarray in NK150460 treated breast cancer cell lines.
Supplementary Table 2 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Table 2. Growth inhibitory activities of NK150460 against various cancer cell lines.
Supplementary Table 1 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Table 1. Growth inhibitory activities of NK150460 and tamoxifen against various cancer cell lines.
Supplementary Table 1 from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

Sequences of primers used.
Supplementary Figure 1 from A Novel Compound, NK150460, Exhibits Selective Antitumor Activity against Breast Cancer Cell Lines through Activation of Aryl Hydrocarbon Receptor
Authors: Fukasawa Kazuteru , Kagaya Shigehide , Maruyama Sakiko , Kuroiwa Shunsuke , Masuda Kuniko , Kameyama Yoshio , Satoh Yoshitaka , Akatsu Yuichi , Tomura Arihiro , Nishikawa Kiyohiro , Horie Shigeo , Ichikawa Yuh-ichiro
Published: April 2023

Supplementary Figure 1. Effect of CYP1B1 siRNA on growth inhibitory activity of NK150460 in breast cancer cell line SK-BR-3.
Supplementary Figure 1 from Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells
Authors: Tögel Lars , Nightingale Rebecca , Chueh Anderly C. , Jayachandran Aparna , Tran Hoanh , Phesse Toby , Wu Rui , Sieber Oliver M. , Arango Diego , Dhillon Amardeep S. , Dawson Mark A. , Diez-Dacal Beatriz , Gahman Timothy C. , Filippakopoulos Panagis , Shiau Andrew K. , Mariadason John M.
Published: April 2023

BET protein expression in 20 colon cancer cell lines.
Table S1 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Table S1. Ingenuity Pathways upstream analysis correlates SW044248 with inhibitors of topoisomerases and other DNA damaging agents.
Supplementary Figure legends from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

This document contains all the supplementary figure legends.
Figure S4 from A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non–Small Cell Lung Cancer Cell Lines
Authors: Zubovych Iryna O. , Sethi Anirudh , Kulkarni Aditya , Tagal Vural , Roth Michael G.
Published: April 2023

Figure S4. SW044248 inhibits Top 1 differently from camptothecin.
Wilsbacher et. al. supplement from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Authors: Wilsbacher Julie L. , Cheng Min , Cheng Dong , Trammell Samuel A.J. , Shi Yan , Guo Jun , Koeniger Stormy L. , Kovar Peter J. , He Yupeng , Selvaraju Sujatha , Heyman H. Robin , Sorensen Bryan K. , Clark Richard F. , Hansen T. Matthew , Longenecker Kenton L. , Raich Diana , Korepanova Alla V. , Cepa Steven , Towne Danli L. , Abraham Vivek C. , Tang Hua , Richardson Paul L. , McLoughlin Shaun M. , Badagnani Ilaria , Curtin Michael L. , Michaelides Michael R. , Maag David , Buchanan F. Gregory , Chiang Gary G. , Gao Wenqing , Rosenberg Saul H. , Brenner Charles , Tse Chris
Published: April 2023

Supplementary methods, tables S1-S3, and supplementary figures 1-7
Supplementary Figure S4: Evaluation of the treatment effects on luciferase activity in peritoneal dissemination xenografted mouse model bearing SKOV-3/Luc cells from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Authors: Ishida Michihiro , Kagawa Shunsuke , Shimoyama Kyoko , Takehara Kiyoto , Noma Kazuhiro , Tanabe Shunsuke , Shirakawa Yasuhiro , Tazawa Hiroshi , Kobayashi Hisataka , Fujiwara Toshiyoshi
Published: April 2023

A, We monitored the bioluminescence intensity of the peritoneal dissemination and compared the total fluorescence. Before treatment, mice with approximately the same luciferase intensity were selected and randomized. The time course of the bioluminescence images of tumor-bearing mice after treatment in vivo. B, The quantitative luciferase activity in mice after treatment. The total fluorescence of the integrated therapy group was remarkably suppressed as compared to that of controls. (n= 5 mice in each treatment group; *P< 0.05 vs control group using one-way repeated ANOVA).
Supplementary Figure S3: The characteristics of SKOV-3/Luc cells from Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer
Authors: Ishida Michihiro , Kagawa Shunsuke , Shimoyama Kyoko , Takehara Kiyoto , Noma Kazuhiro , Tanabe Shunsuke , Shirakawa Yasuhiro , Tazawa Hiroshi , Kobayashi Hisataka , Fujiwara Toshiyoshi
Published: April 2023

The characteristics of SKOV-3/Luc cells. The human ovarian cancer cell line SKOV-3/Luc is known to be HER2-positive. A, Western blot analysis showed the expression of wt-HER2 protein (185 kDa) in SKOV-3/Luc cells, the same as in N87 cells. B, In flow cytometric analysis, the high HER2 expression level was confirmed in SKOV-3/Luc cells, as compared with in the parental cells. C, Immunohistochemistry showed diffuse HER2 expressions on SKOV-3/Luc cells. D, SKOV-3/ Luc cells seeded on 96-well plates at a density of 2ï‚'103 cells/ well for 24 h. Trastuzumab and Tra-IR700 were added (10 Î¼g /mL) for 6 h, and NIR light was irradiated at 5 J/cm2. Forty-eight h after the irradiation, the cell viability was assessed. Tra-IR700-mediated PIT efficiently decreased the cell viability. *BF, bright field; ** P< 0.05 vs the other control group using a log-rank test.
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 3 from Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer–siRNA Chimeras in Human Tumor Xenografts
Authors: Ni Xiaohua , Zhang Yonggang , Zennami Kenji , Castanares Mark , Mukherjee Amarnath , Raval Raju R. , Zhou Haoming , DeWeese Theodore L. , Lupold Shawn E.
Published: April 2023

Supplementary Tables: Supplementary Table S1. Sequence of Chemically Synthesized Aptamers and RNA Supplementary Table S2. Sequences of primers for qRT-PCR and 5'RACE. Supplementary Figures: Supplementary Figure S1. 5'RACE analysis of Aptamer siRNA chimera directed cleavage of DNA-PK. Supplementary Figure S2. Stability of A10-3-DNAPK in human and mouse serum. Supplementary Figure S3. Systemic DNA-PK silencing by Aptamer-siRNA chimera.
Supplementary data, Figure 1 from Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells
Authors: Wang Xianhui , Wong Jason , Sevinsky Christopher J. , Kokabee Leila , Khan Faiza , Sun Yan , Conklin Douglas S.
Published: April 2023

Structures of BTK inhibitors. Ibrutinib and AVL-292 are irreversible inhibitors, covalently binding to Cys481 of BTK.
Supplement Figure Legends from Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers
Authors: Sun Kaiming , Atoyan Ruzanna , Borek Mylissa A. , Dellarocca Steven , Samson Maria Elena S. , Ma Anna W. , Xu Guang-Xin , Patterson Troy , Tuck David P. , Viner Jaye L. , Fattaey Ali , Wang Jing
Published: April 2023

Supplement Figure Legends
Supplementary Table 1 from Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma
Authors: Ohata Yoshiteru , Shimada Shu , Akiyama Yoshimitsu , Mogushi Kaoru , Nakao Keisuke , Matsumura Satoshi , Aihara Arihiro , Mitsunori Yusuke , Ban Daisuke , Ochiai Takanori , Kudo Atsushi , Arii Shigeki , Tanabe Minoru , Tanaka Shinji
Published: April 2023

Primers
Supplementary Tables S1-S3 from AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
Authors: Li Cong , Liu Liqin , Liang Lingming , Xia Zhen , Li Zhihong , Wang Xianghong , McGee Lawrence R. , Newhall Katie , Sinclair Angus , Kamb Alexander , Wickramasinghe Dineli , Dai Kang
Published: April 2023

Supplementary Tables S1-S3. Table S1. AMG 925 is a FLT3/CDK4 dual inhibitor; Table S2. AMG 925 resistant cells are also resistant to AC220 and sorafenib; Table S3 AMG 925 activity in Ba/F3 FLT3-ITD cells isolated from AC220 culture expression various FLT3 mutations.
Supplementary Figure 1 from Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
Authors: Finlay Darren , Vamos Mitchell , González-López Marcos , Ardecky Robert J. , Ganji Santhi Reddy , Yuan Hongbin , Su Ying , Cooley Trina R. , Hauser Curt T. , Welsh Kate , Reed John C. , Cosford Nicholas D.P. , Vuori Kristiina
Published: April 2023

PDF - 2226KB, Cell viability assays of A) breast cancer cell lines treated with increasing concentrations of the indicated IAP antagonists, B) cancer cells isolated from a patient mammary tumor fragment pretreated with vehicle or 5 μM of the indicated IAP antagonists for 4 h before treatment with TRAIL for a further 20 h, C) MDA-MB-231 cells pretreated with vehicle or 5 μM of the indicated IAP antagonists for 20 h before treatment with TRAIL for a further 20 h and D) MDA-MB-231 cells pretreated with vehicle, 100 μM 3-FC, 5 μM MLS-0390982 or both for 4 h before treatment with TRAIL for a further 20 h. E) Caspase-3/-7 activity assay with NB7 cells expressing empty vector (NB7+Empty Vector), caspase-8 or inactive caspase-8 (C360A) pretreated with 5 μM SBI-0636457 before treatment with 100 ng/mL TRAIL for 4 h. Activity is in relative units.
Supplementary Table 1 from Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells
Authors: Zhou Yan , Zhao Conghui , Gery Sigal , Braunstein Glenn D. , Okamoto Ryoko , Alvarez Rocio , Miles Steven A. , Doan Ngan B. , Said Jonathan W. , Gu Jiang , Phillip Koeffler H.
Published: April 2023

PDF - 60KB, Antibodies for Western blotting.
Supplementary Figure S1 from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

miR-29b targets HDAC4 in SKMM1 cells
Legends to Supplementary Table and Figures from Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Authors: Amodio Nicola , Stamato Maria Angelica , Gullà Anna Maria , Morelli Eugenio , Romeo Enrica , Raimondi Lavinia , Pitari Maria Rita , Ferrandino Ida , Misso Gabriella , Caraglia Michele , Perrotta Ida , Neri Antonino , Fulciniti Mariateresa , Rolfo Christian , Anderson Kenneth C. , Munshi Nikhil C. , Tagliaferri Pierosandro , Tassone Pierfrancesco
Published: April 2023

Legends to Supplementary Table and Figures
Supplementary Figure 1: Dinaciclib potentiates cytotoxic effects of doxorubicin from A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition
Authors: Alagpulinsa David A. , Ayyadevara Srinivas , Yaccoby Shmuel , Shmookler Reis Robert J.
Published: April 2023

MM.1S (A) and H929 (B) cell lines were treated with doxorubicin (DOX; 0â€’160 nM) {plus minus}ï‚± dinaciclib (SCH; 20 nM); viable cell number was assessed by WST-1 after 72h. Mean survival {plus minus} SEM is shown for 3 replicate experiments normalized to the untreated controls, and statistical comparisons were made by 2-tailed paired t-tests against SCH treatment alone (open bar, DOX = 0 nM), with the exception of SCH treatment, which was compared to its control treatment (i.e. filled vs. open bar, at DOX = 0 nM). *, **, *** and **** indicate p<0.05, 0.01, 0.001, and 0.0001, respectively.
Figure S3 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

The RTK phosphorylation profile-based combinational treatment was cell-type independent but RTK phosphorylation pattern-dependent.
Figure S2 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Targeting activated RTKs was essential to inhibit cancer cell growth.
Figure S1 from Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Authors: Sun Xiaoxiao , Song Qiaoling , He Li , Yan Lei , Liu Jingli , Zhang Qing , Yu Qiang
Published: April 2023

Multiple RTKs were activated in cancer cells.
Supplementary Figures Legends from ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer
Authors: Ruiz de Sabando Ainara , Wang Chao , He Yuanjun , García-Barros Mónica , Kim Julie , Shroyer Kenneth R. , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

Supplementary Figures Legends
Supplementary Figure 1 from ML264, A Novel Small-Molecule Compound That Potently Inhibits Growth of Colorectal Cancer
Authors: Ruiz de Sabando Ainara , Wang Chao , He Yuanjun , García-Barros Mónica , Kim Julie , Shroyer Kenneth R. , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

ML264 effects on the rate of apoptosis in colorectal cancer cell lines.
Supplementary Table S2. Comparison of morphometric parameters from Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response
Authors: Cerles Olivier , Benoit Evelyne , Chéreau Christiane , Chouzenoux Sandrine , Morin Florence , Guillaumot Marie-Anne , Coriat Romain , Kavian Niloufar , Loussier Thomas , Santulli Pietro , Marcellin Louis , Saidu Nathaniel E.B. , Weill Bernard , Batteux Frédéric , Nicco Carole
Published: April 2023

Mean values {plus minus} SD of morphometric parameters of single myelinated axons isolated from sciatic nerves of mice injected with vehicle, oxaliplatin, oxaliplatin plus niclosamide or niclosamide alone, for 5 weeks (271-319 axons from 4 different mice under each condition).
Supplementary Table S1. Comparison of neuromuscular excitability parameters from Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response
Authors: Cerles Olivier , Benoit Evelyne , Chéreau Christiane , Chouzenoux Sandrine , Morin Florence , Guillaumot Marie-Anne , Coriat Romain , Kavian Niloufar , Loussier Thomas , Santulli Pietro , Marcellin Louis , Saidu Nathaniel E.B. , Weill Bernard , Batteux Frédéric , Nicco Carole
Published: April 2023

Derived excitability parameters (means {plus minus} SD) from plantar muscle recordings in response to motor sciatic nerve stimulation of mice treated for 5 weeks with vehicle (n = 6), oxaliplatin (n = 7), oxaliplatin plus niclosamide (n = 9) or niclosamide alone (n = 7). Each group was compared to animals injected with vehicle, and differences were considered significant when P < 0.05 (highlighted in grey). Note that, when compared to vehicle-treated mice, all the parameters modified in oxaliplatin-injected mice remain constant when oxaliplatin plus niclosamide or niclosamide alone was administered.
Supplementary Figure S1 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Authors: Kato Akihisa , Kataoka Hiromi , Yano Shigenobu , Hayashi Kazuki , Hayashi Noriyuki , Tanaka Mamoru , Naitoh Itaru , Ban Tesshin , Miyabe Katsuyuki , Kondo Hiromu , Yoshida Michihiro , Fujita Yasuaki , Hori Yasuki , Natsume Makoto , Murakami Takashi , Narumi Atsushi , Nomoto Akihiro , Naiki-Ito Aya , Takahashi Satoru , Joh Takashi
Published: April 2023

Cell viability in pancreatic cancer cells treated by talaporfin with or without irradiation.
Supplementary Tables 1-5 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

Supplementary Table 1. Metrics of the RNA-Seq experiment; Supplementary Table 2. Clinical and pathological characteristics of patients whose tumors were analyzed for CHKA expression; Supplementary Table 3. IC50 of MN58b for the PDAC cell lines used in the study; Supplementary Table 4. IC50 for gemcitabine, oxaliplatin, and 5-FU in control (ShNt, non-targetting) and CHKA-knockdown (Sh-1 and Sh-2) cells; Supplementary Table 5. Effect of modulation of ABCB transporter activity on the sensitivity (IC50) to treatment with MN58b of IMIM-PC-2 and IMIM-PC-2R cells.
Supplementary Figure 3 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

CHKA expression in HPNE cells and pancreas cancer cells
Supplementary Figure 2 from Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors
Authors: Mazarico José M. , Sánchez-Arévalo Lobo Victor J. , Favicchio Rosy , Greenhalf William , Costello Eithne , Carrillo-de Santa Pau Enrique , Marqués Miriam , Lacal Juan C. , Aboagye Eric , Real Francisco X.
Published: April 2023

CHKA expression in tissues and cell lines
All supplemental figures from Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds
Authors: Chan Jie Ying , Hackel Benjamin J. , Yee Douglas
Published: April 2023

All supplemental figures
'Supplementary Tables' from Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
Authors: Gimenez-Xavier Pol , Pros Eva , Bonastre Ester , Moran Sebastian , Aza Ana , Graña Osvaldo , Gomez-Lopez Gonzalo , Derdak Sophia , Dabad Marc , Esteve-Codina Anna , Hernandez Mora Jose R. , Salinas-Chaparro Diana , Esteller Manel , Pisano David , Sanchez-Cespedes Montse
Published: April 2023

TABLE S1. Sequences used for primers and for the shRNAs. TABLE S2. List of genes selected from the WES, RNA-seq and microarray methylation analysis
Table S1,Table S2 from Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors
Authors: Zhang Qiang , Xu Jianghao , Qian Yi , Chen Liang , Li Qingya , Xu Kangjing , Chen Ming , Sun Luning , He Zhongyuan , Yang Li , Zhang Diancai , Wang Linjun , Sun Xiaofeng , Wang Yongqing , Xu Hao , Xu Zekuan
Published: April 2023

S1.Detailed SNP information, S2.Relationship of additional SNP and the incidence of rash
Supplementary Table 1 from In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers
Authors: Altwerger Gary , Bonazzoli Elena , Bellone Stefania , Egawa-Takata Tomomi , Menderes Gulden , Pettinella Francesca , Bianchi Anna , Riccio Francesco , Feinberg Jacqueline , Zammataro Luca , Han Chanhee , Yadav Ghanshyam , Dugan Katherine , Morneault Ashley , Ponte Jose F. , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Santin Alessandro D.
Published: April 2023

Endometrioid cell lines with demographics, stage, histologic grade, primary site of tumor, Mean fluorescence intensity (MFI) and score for FRα (folic acid alpha receptor).
Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
Authors: Smith Kristen M. , Fagan Patrick C. , Pomari Elena , Germano Giuseppe , Frasson Chiara , Walsh Colin , Silverman Ian , Bonvini Paolo , Li Gang
Published: April 2023

Characterization of ETV6-NTRK3-driven AML cell lines.
Supplemental Methods and Table S1 and Figures S1-S5 from IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma
Authors: Cardillo Thomas M. , Govindan Serengulam V. , Zalath Maria B. , Rossi Diane L. , Wang Yang , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Supplemental Data Table S1. Area under the curve comparisons between IMMU-140 treated A-375 melanoma-bearing mice and all other treatment groups; Fig. S1. Synthesis Scheme for CL2A-SN-38; Fig. S2. Fluorescent Images of A-375 Spheroids Stained with PI and Calcein AM; Fig. S3. Survival Curves of IMMU-140 versus IMMU-114 Treatment of Disseminated Xenograft Disease Models of Human ALL, AML, MM, and CLL; Fig. S4. Tolerability of IMMU-140 Combined with Doxorubicin or Bortezomib in SCID Mice; Fig. S5. HLA-DR a-Chain Expression on Hematological Cancer Xenografts.
Supplementary Table 2 from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Authors: Tu Xinyi , Kahila Mohamed M. , Zhou Qin , Yu Jia , Kalari Krishna R. , Wang Liewei , Harmsen William S. , Yuan Jian , Boughey Judy C. , Goetz Matthew P. , Sarkaria Jann N. , Lou Zhenkun , Mutter Robert W.
Published: April 2023

Supplementary Table 2 demonstrates single nucleotide variants, indels, copy number variants and copy number alterations in MCTNBC2
Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Authors: Huang Yan , Hu Wei , Huang Jie , Shen Fangrong , Sun Yunjie , Ivan Cristina , Pradeep Sunila , Dood Robert , Haemmerle Monika , Jiang Dahai , Mangala Lingegowda S. , Noh Kyunghee , Hansen Jean M. , Dalton Heather J. , Previs Rebecca A. , Nagaraja Archana S. , McGuire Michael , Jennings Nicholas B. , Broaddus Russell , Coleman Robert L. , Sood Anil K.
Published: April 2023

Supplementary Figure 1. In vitro effects of PR silencing on onapristone sensitivity in PR-high-expressing uterine cancer cell line (Ishikawa). Supplementary Figure 2. In vitro effects of onapristone and trametinib in PR-weak-expressing uterine cancer cell line (SKUT2). Supplementary Figure 3. In vivo effects of therapy with onapristone in uterine cancer model. Supplementary Figure 4. In vivo effect of onapristone, trametinib, and the combination of both drugs on total PR expression in the ISHIKAWA model.
Supplemental Figure 1 legend from miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases
Authors: Yang Yuanzheng , Huang Gangxiong , Zhou Zhichao , Fewell Jason G. , Kleinerman Eugenie S.
Published: April 2023

Supplemental Figure 1 legend
Supplementary Figure 2 from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Authors: Tu Xinyi , Kahila Mohamed M. , Zhou Qin , Yu Jia , Kalari Krishna R. , Wang Liewei , Harmsen William S. , Yuan Jian , Boughey Judy C. , Goetz Matthew P. , Sarkaria Jann N. , Lou Zhenkun , Mutter Robert W.
Published: April 2023

Supplementary Figure S2 demonstrates individual tumor volume data of MCTNBC1, MCTNBC2, MCTNBC3, and MCTNBC4 for the experiment shown in figure 5.
Supplementary Tables 1-3 from Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Authors: Namløs Heidi M. , Boye Kjetil , Mishkin Skyler J. , Barøy Tale , Lorenz Susanne , Bjerkehagen Bodil , Stratford Eva W. , Munthe Else , Kudlow Brian A. , Myklebost Ola , Meza-Zepeda Leonardo A.
Published: April 2023

Supplementary Table 1. A detailed overview of the somatic KIT and PDGFRA mutations found in the tumour, and somatic mutations found in plasma of the 50 GIST patients; Supplementary Table 2. Overview of mutated allele frequencies of the somatic mutations identified in tumour and plasma samples from the GIST case patient; Supplementary Table 3. Somatic KIT mutations identified in FFPE blocks collected at time of surgery from 10 different parts of the imatinib treated tumour of the case patient #50.